-- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with...
NAARDEN, The Netherlands and MIAMI, Aug. 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying...
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
NAARDEN, The Netherlands and MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
NAARDEN, The Netherlands and MIAMI, July 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
-- New patent extends patent term for obicetrapib until July 2043 -- NAARDEN, the Netherlands and MIAMI, June...
NAARDEN, the Netherlands and MIAMI, June 07, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
NAARDEN, the Netherlands and MIAMI, May 29, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating...
-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase...
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
NAARDEN, the Netherlands and MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.